What question did this study set out to answer?

January 17, 2026

Mesothelioma Contrast Pharmacokinetics: A Feasibility Trial of the Use of Pharmacokinetic Analysis in Small-Volume Pleural Malignancy

GCGordon W. CowellNHS Greater Glasgow and Clyde STSelina TsimNHS Greater Glasgow and Clyde DSDavid StoboQueen Elizabeth University Hospital

Key Points

To evaluate the feasibility of pharmacokinetic analysis of dynamic contrast-enhanced MRI data in small-volume pleural malignancy.
Conducted pharmacokinetic analysis using dynamic contrast-enhanced MRI data
Assessed sensitivity for malignant detection through morphologic evaluation
Investigated the effect of early contrast enhancement on detection accuracy.
Pharmacokinetic analysis was found to be feasible in small-volume pleural disease
Sensitivity for detecting malignancy improved when combined with morphological assessment
Early contrast enhancement positively influenced detection sensitivity.

Abstract

Pharmacokinetic analysis of dynamic contrast-enhanced MRI data was feasible in small-volume pleural disease, with sensitivity for malignant detection increasing when combined with morphologic assessment and the presence of early contrast enhancement.

Demander à l'IA

Bookmark

View Full Paper